Wechselwirkungen · Reyataz
REYATAZ 200 mg hard capsules REYATAZ 300 mg hard capsules · Abschnitt 4.5 · PDF-Seite 19–20
HOS-112103 · Präparat HOS-093615
19 Medicinal products by Interaction Recommendations concerning co- therapeutic area administration Calcium channel blockers Bepridil REYATAZ should not be used in Co-administration with bepridil is combination with medicinal products that contraindicated (see section 4.3) are substrates of CYP3A4 and have a narrow therapeutic index. Diltiazem 180 mg once daily Diltiazem AUC: ↑125% (↑109% ↑141%) An initial dose reduction of (atazanavir 400 mg once daily) Diltiazem Cmax: ↑98% (↑78% ↑119%) diltiazem by 50% is recommended, Diltiazem Cmin: ↑142% (↑114% ↑173%) with subsequent titration as needed and ECG monitoring. Desacetyl-diltiazem AUC: ↑165% (↑145% ↑187%) Desacetyl-diltiazem Cmax: ↑172% (↑144% ↑203%) Desacetyl-diltiazem Cmin: ↑121% (↑102% ↑142%)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diltiazem (HOS-086288) bepridil (HOS-085612) calcium (HOS-085615)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-29T13:00:00Z · SHA-256 ff5481974bd7c752b73fa0c147cf3e96fc892edc735359fa71817833db471beb · Passage a5938ef1523f856eb59b74422c7cfaea01c48399a19f2b7a8ea958d4d8e50ef3 · Zeichen 51161–52517 im Abschnitt